Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05602818 · ClinicalTrials.gov registry record · Phase 1
A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT05602818 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 100 participants.
The verdict
NCT05602818, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
The main aim is to evaluate the relative abuse potential of soticlestat in healthy adults who has used central nervous system (CNS) depressants for recreational nontherapeutic reasons.
Interventions
- DRUG Placebo
- DRUG Alprazolam
- DRUG Soticlestat 300 mg
- DRUG Soticlestat 600 mg
- DRUG Soticlestat 900 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2023-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05602818
The ClinicalTrials.gov registry entry for NCT05602818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05602818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05602818 about?
NCT05602818 is a clinical study titled "A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience". The main aim is to evaluate the relative abuse potential of soticlestat in healthy adults who has used central nervous system (CNS) depressants for recreational nontherapeutic reasons.
What is the current status of trial NCT05602818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2022-11-15. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT05602818?
The interventions under investigation include: Placebo (DRUG), Alprazolam (DRUG), Soticlestat 300 mg (DRUG), Soticlestat 600 mg (DRUG), Soticlestat 900 mg (DRUG).
Who is sponsoring clinical trial NCT05602818?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.